Thymidine 3',5'-diphosphate tetrasodium (0.8 mg/kg; i.p.; twice a week for 4 weeks) has insignificant effect on serum liver enzymes (AST, ALT, AP), total protein (TP), albumin (Alb), and globulin (Glo) in WT B6/CBA mice[1].
Thymidine 3',5'-diphosphate tetrasodium (0.8 mg/kg and 1.6 mg/kg; i.v.; twice a week for 4 weeks) significantly inhibits tumor growth in WT B6/CBA mice[1].
Thymidine 3',5'-diphosphate tetrasodium (0.8, 0.16 and 0.32 mg/kg; s.c.; twice a week for 4 weeks) inhibits tumor growth, inflammatory reaction and the expression of tumor initiating cells (TIC) markers in adult male NSG mice. Thymidine 3',5'-diphosphate tetrasodium up-regulates the expression of PTEN, TGFBR2 and CDKN1C apoptosis and selective tumor suppressor genes[1].
| Animal Model: | 2 months old WT B6/CBA mice[1]. |
| Dosage: | 0.8 mg/kg. |
| Administration: | Intraperitoneal injection; twice a week for 4 weeks. |
| Result: | Had insignificant effect on serum liver enzymes, total protein, albumin and globulin and showed biosafety. |
| Animal Model: | NSG mice[1]. |
| Dosage: | 0.8, 0.16 or 0.32 mg/kg. |
| Administration: | Intravenous injection or subcutaneous injection; twice a week for 4 weeks. |
| Result: | Inhibited tumor growth, showed antitumor activity and immunomodulatory effects.
|
